PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 296.7K (Avg.)
-1.36 | -1.31
Steady, sustainable growth is a hallmark of high-quality businesses. Value investors watch these metrics to confirm that the company's fundamental performance aligns with—or outpaces—its current market valuation.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
30.34%
EBIT growth 50-75% of AGEN's 46.66%. Martin Whitman would suspect suboptimal resource allocation.
30.35%
Operating income growth at 50-75% of AGEN's 46.34%. Martin Whitman would doubt the firm’s ability to compete efficiently.
30.26%
Net income growth at 75-90% of AGEN's 33.91%. Bill Ackman would press for improvements to catch or surpass competitor performance.
30.58%
EPS growth at 75-90% of AGEN's 35.10%. Bill Ackman would push for improved profitability or share repurchases to catch up.
33.88%
Similar diluted EPS growth to AGEN's 35.10%. Walter Schloss might see standard sector or cyclical influences on both firms.
0.94%
Share reduction more than 1.5x AGEN's 1.90%. David Dodd would see if the company is taking advantage of undervaluation to retire shares.
5.92%
Diluted share count expanding well above AGEN's 1.90%. Michael Burry would fear significant dilution to existing owners' stakes.
No Data
No Data available this quarter, please select a different quarter.
10.50%
Positive OCF growth while AGEN is negative. John Neff would see this as a clear operational advantage vs. the competitor.
10.43%
Positive FCF growth while AGEN is negative. John Neff would see a strong competitive edge in net cash generation.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-10668.67%
Both show negative 10Y OCF/share CAGR. Martin Whitman would question if the entire market or product set is shrinking or too capital-intensive.
79.98%
Positive OCF/share growth while AGEN is negative. John Neff might see a comparative advantage in operational cash viability.
60.25%
Positive 3Y OCF/share CAGR while AGEN is negative. John Neff might see a big short-term edge in operational efficiency.
-3178.86%
Both face negative decade-long net income/share CAGR. Martin Whitman would suspect a shrinking or highly disrupted sector.
82.89%
5Y net income/share CAGR above 1.5x AGEN's 48.15%. David Dodd would confirm if the firm’s strategy is more effective in generating mid-term profits.
76.87%
3Y net income/share CAGR above 1.5x AGEN's 28.28%. David Dodd would confirm the company’s short-term strategies outmatch the competitor significantly.
496.60%
Positive growth while AGEN is negative. John Neff might see a strong advantage in steadily compounding net worth over a decade.
159.22%
Positive 5Y equity/share CAGR while AGEN is negative. John Neff might see a clear edge in retaining earnings or managing capital better.
-89.45%
Both show negative short-term equity/share CAGR. Martin Whitman suspects an industry slump or unprofitable expansions for both players.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-28.48%
Both reduce assets yoy. Martin Whitman suspects a broader sector retraction or post-boom asset trimming cycle.
-43.72%
Both erode book value/share. Martin Whitman suspects a difficult environment or poor capital deployment for both players.
14.13%
We have some new debt while AGEN reduces theirs. John Neff sees the competitor as more cautious unless our expansions pay off strongly.
-30.15%
Both reduce R&D yoy. Martin Whitman sees an industry shifting to cost reduction or limited breakthroughs in the near term.
-30.87%
We cut SG&A while AGEN invests at 7.00%. Joel Greenblatt sees a short-term margin benefit but wonders if the competitor invests for future gains.